Trilaciclib Clinical Trials
8 recruitingDrug
Phase 26Phase 41Phase 31
Showing 1–8 of 8 trials
Recruiting
Phase 3
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Pharmacosmos A/S120 enrolled1 locationNCT07473128
Recruiting
Phase 2
Study of Trilaciclib and Lurbinectidin
Lung CancerSmall Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center30 enrolled2 locationsNCT05578326
Recruiting
Phase 4
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Extensive-stage Small-cell Lung Cancer
Pharmacosmos A/S302 enrolled1 locationNCT05874401
Recruiting
Phase 2
Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Triple-Negative Breast Cancer
QIAO LI50 enrolled1 locationNCT06955156
Recruiting
Phase 2
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Osteosarcoma
Peking University People's Hospital50 enrolled1 locationNCT06714383
Recruiting
Phase 2
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Lung Cancer, Small Cell
Shanghai Chest Hospital52 enrolled1 locationNCT06698965
Recruiting
Phase 2
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Myelosuppression
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT06490081
Recruiting
Phase 2
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Breast Neoplasms
wang shusen116 enrolled1 locationNCT05978648